Negotiations include recent advances in cycle design
which increases the utility of the STERIZONE(R) 125L Sterilizer
Stock symbol: TSX: TOS
Outstanding shares: 47,863,402
QUEBEC CITY, Sept. 2 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX:TOS) is
pleased to announce that it has entered into a 90 day exclusive negotiation
period with 3M (NYSE: MMM), a leader in the Infection Prevention Market with
operations in over 60 countries, for the purpose of completing a global
channel partner agreement. These negotiations are pursuant to a signed Letter
of Intent and Term Sheet between the companies, involving the exclusive supply
and distribution of TSO3's STERIZONE(R) 125L Sterilizer for acute care
facilities through 3M's global sales channel.
The company also announced that included in the negotiations are advances
in cycle design recently defined by TSO3, which will be included as part of
the product as well as offered to existing customers once cleared by the
appropriate regulatory agencies. These advances include additional cycles all
substantially faster then the current cycle and all with improved materials
compatibility. These cycles are tailored towards a defined set of customer
"We are pleased to begin definitive negotiations with 3M", commented Mr.
Ric Rumble TSO3's President and CEO. "We firmly believe that our technology,
including recent advances in cycle design, offers global market appeal. 3M is
the recognized global innovator in sterility assurance products and as the
market leader in 100% Ethylene Oxide sterilization systems, has a long and
respected history in the low temperature sterilization market segment. The
combination of our products and their sales and marketing capabilities create
increased commercial strength."
TSO3 has outlined in the past its plans to engineer additional cycles
that could be added to the existing sterilizer, in order to offer increased
utility of the device for both current and future customers. "Our work in this
area has been extremely rewarding and we are very pleased with the reaction to
our advances in cycle development. Plans and timelines to submit the new
cycles for regulatory clearance are set and we are diligently working to meet
these milestones. More details about these new cycles will be available
shortly" continued Mr. Rumble.
"We were very impressed with the capabilities of the TSO3 STERIZONE(R)
Sterilizer and the utility it offers to increase sterilization throughput in a
cost effective, fast and eco-friendly manner. 3M has a long history of
bringing innovative products and services to the sterilization assurance
marketplace and we look forward to finalizing an agreement with TSO3 to sell
the STERIZONE(R) 125L Sterilizer through our operations worldwide", said Debra
Rectenwald, Vice President and General Manager, 3M Infection Prevention
Over the past months, TSO3 has outlined its desire to accomplish
increased utility of its sterilizer, develop relationships leading to a
channel partner and increase market opportunities via expansion outside of
North America. "While still a work in progress, we are more than pleased with
the tangible progress in each of these areas", concluded Mr. Rumble.
About 3M Infection Prevention Division
The 3M Infection Prevention Division offers healthcare professionals
leadership solutions to minimize the risks of healthcare-associated
infections. Combining science and technology, 3M Infection Prevention is built
upon more than 40 distinct technology platforms and a comprehensive portfolio
of quality products that help the healthcare industry define and address
current infection prevention best practices. 3M Infection Prevention remains a
trusted partner committed to helping customers lead the way in detecting,
preventing and controlling the risk of infection. For more information, visit
A recognized leader in research and development, 3M produces thousands of
innovative products for dozens of diverse markets. 3M's core strength is
applying its more than 40 distinct technology platforms - often in combination
- to a wide array of customer needs. With $24 billion in sales, 3M employs
75,000 people worldwide and has operations in more than 60 countries. For more
information, visit www.3M.com.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers
in the hospital environment. The Company believes that its technology
represents an advantageous replacement solution to other low temperature
sterilization processes currently used in hospitals.
In contrast to other methods, the ozone sterilization process developed
and patented by TSO3 meets all standards required by the evolution in
sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by
the US and Canadian regulatory agencies for sterilization of metal and heat
sensitive instruments, as well as for devices with diffusion-restricted
spaces, such as the hinged portion of haemostats, forceps and scissors and
rigid endoscopes having a single stainless steel lumen as small as 0.9 mm
internal diameter and 485 mm long. In 2009, the Company received clearance
from Health Canada for sterilization of additional complex medical
instruments, including multi-channelled flexible endoscopes.
For more information about TSO3, visit the Company's Web site at
3M is a registered trademark of 3M Company.
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications and IR, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO3